Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOtorhinolaryngology (ENT)Aetna Hearing Aids Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentAetnaPolicy 0612

    Hearing Aids

    Customize your policy alerts

    Sign up for Aetna Policy 0612 alerts

    Get alerted when Policy 0612 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing medical necessity, coverage, and exclusions for air conduction, implantable, and semi-implantable hearing aids for Aetna members and guidance for plans that do not exclude hearing aids.

    Policy Summary
    PayerAetna
    PolicyHearing Aids
    Policy CodePolicy 0612
    Change TypeNo material change
    Effective DateMay 3, 2002
    Last ReviewSep 12, 2023
    Next Review DateJul 11, 2024
    Key ActionFor plans that cover hearing aids, document medical necessity and obtain any required authorization per the member's benefit plan when selection criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    40 dBhearing threshold criterion

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    26 dB x3alternate threshold
    <94%speech recognition
    Most excludebenefit plan limitation
    8RCTs/studies cited
    2010Esteem FDA

    Coverage and Medical Necessity Criteria

    Medically necessary indications

    Aetna considers the following medically necessary:

    Air conduction hearing aids

    • Hearing threshold criteria: Hearing thresholds >= 40 dB HL at 500, 1000, 2000, 3000, or 4000 Hz; OR hearing thresholds >= 26 dB HL at three of these frequencies.
    • Speech recognition criterion: Speech recognition < 94%.
    Implantable and semi-implantable devices: Covered for members with moderate-to-severe sensorineural hearing impairment who cannot tolerate an ear mold because of medical conditions (e.g., auricular atresia or severe chronic otitis externa).moderate-to-severe sensorineural hearing impairment and intolerance to ear mold

    Examples: Esteem, Carina, Maxum, Vibrant Soundbridge

    OTC and FDA-cleared over-the-counter hearing aids: OTC hearing aids and other FDA-cleared over-the-counter devices are considered equally effective alternatives to prescription-only hearing aids when the member's hearing has been evaluated, medical necessity criteria for air conduction hearing aids are met, and the member has a prescription from a licensed prescriber.FDA clearance and prescription when required

    Applies for plans that do not exclude hearing aids

    Experimental and investigational

    Procedures considered experimental and investigational:

    Experimental / Investigational

    • Balance indication: Air conduction hearing aids for improvement of balance.
    • Other indications: Hearing aids and semi-implantable hearing aids for all other indications, including improvement of depression and cognitive decline in the elderly.
    • Device technology: Use of a free-floating piezoelectric microphone in an implantable hearing aid.

    Most Aetna benefit plans exclude coverage of hearing aids. Any applicable benefit plan exclusions and limitations for coverage of hearing aids apply to air conduction, implantable, and semi-implantable hearing aids. Providers and billing teams should verify the member’s benefit plan for applicable exclusions or limitations before submitting claims, as claims may be denied when the member’s plan does not cover hearing aids.

    Systematic reviews of tinnitus treatments that included hearing aids, sound generators, and combination devices found no clear evidence that sound therapy is superior to waiting-list control, placebo, or education/information only. The evidence was generally low quality and limited by risk of bias and sparse data, which limits claims that sound therapy provides superior clinical benefit for tinnitus.

    Use of hearing aids to treat non-auditory conditions such as major depressive disorder, vestibular/vertiginous disorders, or age‑related cognitive decline is not supported as covered indications in this policy. The CPB lists ICD-10 codes for these conditions as not covered for the indications described; clinicians should exercise caution and document that the primary indication for a hearing aid is auditory impairment that meets the medical necessity criteria if coverage is being pursued.

    Evidence comparing bilateral versus unilateral hearing aids for adults with bilateral hearing impairment is limited and of very low quality. Small, heterogeneous randomized trials with older-generation devices produced inconsistent patient preference results and did not provide robust data on quality‑of‑life or audiometric outcomes. The CPB therefore notes insufficient evidence to conclude a clear superiority of bilateral over unilateral fitting for coverage purposes, and this should be considered when documenting medical necessity and device selection.

    Coding and Clinical Thresholds

    HCPCS covered if selection criteria metHCPCSCovered
    S2230Implantation of magnetic component of semi-implantable hearing device on ossicles in middle ear.
    V5030Hearing aid, monaural, body worn, air conduction.
    V5050Hearing aid, monaural, in the ear.
    V5070Glasses, air conduction.
    V5095Semi-implantable middle ear hearing prosthesis.
    ICD-10 covered if selection criteria metICD-10Covered
    H90.3 - H90.8Sensorineural hearing loss and mixed conductive and sensorineural hearing loss.
    Q16.1Congenital absence, atresia and stricture of auditory canal (external).
    ICD-10 codes not covered for indications listed in the CPBICD-10Not Covered
    F32.0 - F32.9Major depressive disorder, single episode.
    F33.0 - F33.9Major depressive disorder, recurrent.
    H81.311 - H81.399Other peripheral vertigo.
    H81.8X1 - H81.8X9Other disorders of vestibular function.
    H81.90 - H81.93Unspecified disorder of vestibular function.
    H82.1 - H82.9Vertiginous syndromes in diseases classified elsewhere.
    R41.81Age-related cognitive decline.
    No explicit CPT/HCPCS/ICD-10 codes in these chunksmixed
    No codes listed
    Hearing thresholds
    Primary threshold>= 40 dB HL at 500, 1000, 2000, 3000, or 4000 Hz
    Alternative threshold>= 26 dB HL at any three of these frequencies (500, 1000, 2000, 3000, 4000 Hz)
    ContextApplies to coverage determination for air conduction hearing aids when selection criteria are evaluated
    Speech recognition
    Speech recognition criterionSpeech recognition less than 94%
    Use caseOne of the coverage selection criteria for air conduction hearing aids

    Provider Responsibilities and Billing Guidance

    Billing Rule

    Billing guidance & documentation

    Coverage of HCPCS and ICD-10 codes in this policy is contingent on meeting the selection/medical necessity criteria. Providers should verify member benefits and document medical necessity (pre- and post-operative thresholds, Merchant grade, surgical outcomes, and relevant audiometric testing) when submitting claims.

    • Verify member benefit plan for hearing aid coverage — many Aetna plans exclude hearing aids and claims may be denied if excluded.
    • Document pre- and post-operative audiometric thresholds, Merchant grade, and surgical outcomes as captured in cited studies (e.g., Geerse et al. 2020).
    Prior Authorization

    Prior authorization not specified

    This section does not specify any payer-level prior authorization requirements. Providers should still check the member’s benefit plan and any applicable medical management rules before scheduling services.

    Background and Context

    Implantable and semi-implantable middle ear hearing devices (for example, the Vibrant Soundbridge, the Esteem totally implantable system, and devices such as the Carina) are alternatives to conventional hearing aids for selected patients with moderate‑to‑severe sensorineural, conductive, or mixed hearing loss. Indications commonly include patients who cannot tolerate ear molds (for example, congenital external auditory canal atresia or severe chronic otitis externa) or those for whom conventional amplification is not feasible. Clinical outcomes vary by device and population, and the policy limits coverage of these devices to members who meet the specific medical necessity criteria described in the policy.

    Device Definitions

    Vibrant Soundbridge (semi-implantable system)
    DefinitionA semi-implantable system comprising an internally implanted Floating Mass Transducer (FMT) and an externally worn Audio Processor that transmits sound across the skin to the implanted receiver; the FMT vibrates the ossicles to stimulate the cochlea.
    ComponentsImplanted FMT and external Audio Processor (AP)
    IndicationAlternative to external hearing aids for adults with moderate-to-severe sensorineural hearing loss, especially when ear mold intolerance exists
    Esteem Totally Implantable Hearing System
    DefinitionA fully implantable hearing system that uses piezoelectric transducers to sense eardrum vibrations, convert them to electrical signals for internal processing/amplification, and deliver a processed vibratory signal to the ossicular chain.
    FDA note

    Policy History and Review Dates

    2002-05-03Effective date

    Policy became effective on May 3, 2002.

    2023-09-12Last review

    Policy was last reviewed on September 12, 2023.

    2024-07-11Next reviewLatest

    Next scheduled policy review is July 11, 2024.

    Policy Summary
    PayerAetna
    PolicyHearing Aids
    Policy CodePolicy 0612
    Change TypeNo material change
    Effective DateMay 3, 2002
    Last ReviewSep 12, 2023
    Next Review DateJul 11, 2024
    Key ActionFor plans that cover hearing aids, document medical necessity and obtain any required authorization per the member's benefit plan when selection criteria are met.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCoding and Clinical ThresholdsProvider Responsibilities and Billing GuidanceBackground and ContextDevice DefinitionsPolicy History and Review Dates
    NotesMeasured as part of audiologic evaluation when determining medical necessity
    • No prior authorization requirement is stated in this policy section.
    • Confirm any prior authorization requirements with the member’s plan or via normal benefit verification processes.
    Prior Authorization

    Prior authorization — provider action

    Although prior authorization is not specified here, providers should be prepared to obtain authorization if required by the member’s benefit plan and to supply supporting documentation for medical necessity.

    • If the benefit plan requires prior authorization, include audiometric test results, history of hearing aid use/intolerance (for implantable options), and surgical notes.
    • For Vibrant Soundbridge or other implantable devices, document that appropriately fit hearing aids were tried prior to implantation when applicable.
    Step Therapy

    Step therapy not addressed

    Step therapy or step-wise treatment requirements are not addressed in this policy section. There are no described step therapy requirements for hearing aids or implantable devices within these background and coding blocks.

    • No step-therapy policies or staged treatment prerequisites are described here.
    • Providers should follow clinical best practices and verify any plan-specific step therapy separately.
    Note

    FDA note — Vibrant Soundbridge (alternative to hearing aids)

    The FDA classifies the Vibrant Soundbridge as a surgically implanted hearing device and notes it may be used as an alternative to traditional hearing aids; adults choosing this device should have already tried appropriately fit hearing aids.

    • Document prior use and intolerance or inadequacy of conventional hearing aids when considering implantable/semi-implantable devices.
    • Include HCPCS code V5095 when billing for the Vibrant Soundbridge where selection criteria are met.
    Denial Risk

    Denial risk — benefit exclusions

    Claims may be denied when applicable benefit plans exclude hearing aids. Verify member coverage before ordering or providing devices and include documentation to support medical necessity.

    • Most Aetna benefit plans exclude coverage of hearing aids — check benefit plan descriptions.
    • If excluded, submit claims cautiously; denials are possible when benefits do not cover hearing aids, implantable or semi-implantable devices.
    Note

    Policy history and review dates

    Policy history and review dates are documented for provider reference; use these dates for currency checks and to reference the most recent policy version.

    • Providers should reference the policy history when citing coverage rationale or when preparing appeals.
    • Policy updates and review history are available via the policy review links.
    Documentation Required

    Not applicable content — no additional payer triggers

    Not applicable / no explicit denial-trigger content is present in the clinical background and study summaries — this part of the section does not define new billing denial triggers beyond benefit exclusions and lack of medical necessity documentation.

    • No additional payer-level denial triggers, prior auth code lists, or step therapy rules are defined in these background chunks.
    • Providers should rely on documented selection criteria, benefit verification, and standard billing guidance.
    Esteem is described in clinical studies and is designed for adults with stable bilateral sensorineural hearing loss; clinical trials report safety and functional benefits (studies cited).
    Implant locationImplanted under the skin behind the ear and within the middle ear space (invisible externally)
    Implantable piezo-driven mechanical amplifier
    DefinitionA transducer concept that uses a piezoelectric sensor and actuators inserted into the incudo‑stapedial joint gap to mechanically amplify high-frequency hearing while employing feedback compensation.
    MechanismPrimary actuator provides output; secondary actuator provides counter force (virtual mass) to reduce feedback; adaptive control used for compensation.
    Performance observedExperimental models reported added stable gain >30 dB and functional hearing gain up to 40 dB in simulations and bench studies.
    Combination hearing aid
    DefinitionA device that combines acoustic amplification and sound generation (e.g., for tinnitus) within a single ear-level device.
    Clinical roleUsed in tinnitus management programs alongside education and advice; compared in trials with hearing aids and sound generators.
    Evidence summaryCochrane review found limited and low-quality evidence with no clear superiority of combination devices over hearing aids or sound generators.
    Canal wall down mastoidectomy cavity (CWDMC) obliteration
    DefinitionSurgical revision (obliteration) of canal wall down mastoidectomy cavities (CWDMCs) to eliminate chronically draining/troublesome cavities and enable rehabilitation.
    Relation to hearing aidsObliteration improves tolerance and ability to use conventional hearing aids; study showed dry ear rate 95% and improved ability to use CHAs from 3% pre-op to 57% post-op.
    OutcomesSignificant improvement in air conduction, bone conduction, and air‑bone gap post-operatively across ossicular reconstructions.
    HAs (shorthand definition)
    DefinitionHAs refers broadly to hearing aids, including conventional air-conduction devices and implantable/semi-implantable devices discussed in the policy and referenced studies.
    ScopeEncompasses over-the-counter, prescription, semi-implantable and fully implantable hearing devices when evaluating clinical outcomes and coverage criteria.
    ContextUsed in policy discussions of effectiveness for outcomes such as hearing function, cognition, depression, and balance.